Emerald Health Therapeutics launches Fuse (TM) lifestyle brand of fast-acting, cannabis-infused beverage

0
8

Nano Shot Product Introduces New Fuse (TM) Brand; leverages Emerald’s science-based innovation to deliver rapid onset of action and more predictable, shorter duration of action

Vancouver, British Columbia – (Newsfile Corp. – July 21, 2021) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) (“Emerald”) has launched its new Fuse ™ lifestyle brand and line of products unveiled latest, the Nano Shot, a flavored, cannabis-infused drink containing 10 mg of THC and a nanoemulsion formulation that guarantees consumers a more predictable, faster onset of action and a shorter controlled duration of action. Initial shipments of the drink are available to consumers at licensed cannabis retailers and online in British Columbia and Manitoba, and are expected to be available in Alberta by the end of the month. They are also available to prescription patients through Emerald’s Direct to Health medical e-commerce site.

Emerald introduces the cannabis-infused Fuse ™ Nano Shot drink in three flavors: apple, mango and frappé

To view an improved version of this image, please visit:
https://orders.newsfilecorp.com/files/3366/90830_8503236ae4077a3b_001full.jpg

The Fuse ™ brand is committed to enhancing consumer “moments” and experiences by offering pocket-sized on-the-go and fast-acting cannabis products that enable users to consume with confidence.

The first Fuse ™ products, Nano Shots, come in a handy 30 ml (one ounce) bottle and offer a 10 mg dose of THC. With the nanoemulsion technology, you achieve the desired effects within 10-20 minutes and last about 90 minutes. The plant-based Nano Shot ingredients are gluten-free and vegan and available in three flavors: apple, mango and frappé.

This new line of products is Emerald’s first line of cannabis beverage products and its second nanoemulsion cannabis product after the launch of its Nano Fast-Action Spray. The nanoscale droplets that are created through the use of this technology significantly improve the bioavailability and absorption of cannabinoids in the body compared to the normal ingestion of cannabis edibles and oils and conventional emulsion approaches – hence the fast-acting effects. The Nano Shot uses Emerald’s Defined DoseTM product attributes to deliver on its brand promise.

The story goes on

“We put a lot of thought and effort into developing the Fuse ™ lifestyle brand and a line of products designed to enhance the social, active or relaxing pursuits of our consumers,” said Kelsi Rourke, director of sales operations, Emerald. “Our unique Nano Shot products are perfect for use on the go, or for enjoying at home during relaxing activities or when meeting friends. Because of the convenience and safe use they offer, we can’t wait to see consumers like this Integrate product into their lifestyle. “

“At Emerald, we apply science-based innovation to create differentiated products with more predictable properties. We brought that to the table with our two most recent product lines and new brand launches,” said Riaz Bandali, President and CEO of Emerald. “This beverage product line adds a familiar form of consumption to one of the fastest growing cannabis product categories while offering consumers more predictable promotions to help them better control their cannabinoid use.”

About FuseTM

Fuse ™ helps novice and seasoned cannabis users welcome good vibes faster and more predictably by offering innovative, science-based cannabis products to elevate experiences quickly and confidently. Whether on the beach, campfire, concert or gaming at home, Fuse products integrate into your lifestyle and electrify every moment when the mood is right.

Find out how to Fuse at: https://letsfuse.ca/

Instagram: https://www.instagram.com/fuse.ca/

About Emerald Health Therapeutics

Emerald is committed to creating new consumer experiences with a variety of recreational, medical and wellness-oriented cannabis products, with an emphasis on innovation and product excellence.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 ext # 5

Emerald Investor Relations
(800) 757 3536 ext # 5
invest@emeraldhealth.ca

Neither the Canadian Securities Exchange nor its regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding Forward-Looking Statements: Certain statements in this press release that are not historical facts are forward-looking statements and are subject to important general and specific risks, uncertainties and assumptions that create the possibility that actual results or events could differ materially from our expectations Be expressed or implied in such forward-looking statements.

We cannot guarantee that forward-looking statements will occur and readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements involve risks and uncertainties relating, among other things, to changes in laws and regulations; Change of government; Failure to obtain regulatory approvals or permits; Failure to obtain the necessary funding; Results of product development, production and sales activities; Changes in the prices and costs of inputs; Demand for products; Changes in business strategy; as well as the risk factors outlined in Emerald’s annual information form and other regulatory filings. The forward-looking statements contained in this press release reflect our expectations as of the date of this press release. Forward-looking statements are presented to provide information about management’s current expectations and plans and to enable investors and others to better understand our anticipated operating environment. Readers are cautioned that this information may not be suitable for other purposes. Emerald undertakes no obligation to update or revise any such statement to reflect new circumstances or unforeseen events as they occur, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90830